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Abstract: Acute coronary syndrome (ACS) in pregnancy has traditionally been considered to be a rare event, but the combination of 
normal physiological changes of pregnancy and more prevalent cardiovascular risk factors are increasing its incidence in this popula-
tion. The present report describes a 39 year-old woman that is seven weeks pregnant presenting with a non ST elevation myocardial 
infarction. The incidence, risk factors, pathophysiology and management of ACS in pregnancy are discussed.
Keywords: Acute coronary syndrome, pregnancy, risk factors, pathophysiologyWright et al
126  Clinical Medicine: Cardiology 2009:3
case Report
A 39 year old female who was seven weeks pregnant 
presented to a community hospital emergency depart-
ment with a first episode of chest pain. She had a 
twenty pack per year smoking history and a significant 
family history of coronary artery disease (CAD) with 
her father developing CAD in his thirties. She had 
no known history of diabetes, dyslipidemia, or hyper-
tension. The pain started after an episode of intense 
vomiting. She described the pain as a pressure sensa-
tion, retrosternal in location, with radiation down both 
arms. It was associated with intense nausea and vom-
iting, and she had some relief with aspirin. The pain 
continued at a high intensity for approximately five 
hours. Given the duration of discomfort and associ-
ated extreme weakness she sought medical attention.
In the emergency department, she denied recre-
ational drug use, and did not have any constitutional 
symptoms. Clinically there was no evidence of deep 
vein thrombosis (DVT), pulmonary embolism (PE), 
or  pericarditis.  On  physical  examination  she  was 
afebrile  and  hemodynamically  stable,  with  a  heart 
rate of 69 and regular, equal blood pressures in both 
arms of 95/65 mmHg, and an oxygen saturation of 
97% on room air. There were no signs of congestive 
heart failure with no pedal edema, clear lungs, and 
no jugular venous distension. The precordial exam 
was normal with no heaves, thrills, normal S1 and S2 
with normal physiological splitting and no extra heart 
sounds, rubs or murmurs. A 12-lead electrocardio-
gram (ECG) was completed that showed normal sinus 
rhythm at a rate of 60 bpm, normal axis, normal inter-
vals with no evidence of chamber enlargement with 
1 mm ST segment depression in lead V4 and 1 mm 
depression in V5 (Fig. 1). Initial blood work showed 
a significant elevation of the cardiac markers with a 
Troponin T of 0.96 µg/L and a creatinine kinase (CK) 
level of 718 U/L, all of which decreased on serial 
measurements. Urine drug screen was negative. An 
echocardiogram  demonstrated  severe  inferolateral 
wall  hypokinesis  with  a  preserved  left  ventricular 
systolic function and ejection fraction of 60% with 
no other abnormalities identified.
This presentation was complicated by a positive 
home pregnancy test. This was confirmed by a quan-
titative β-hCG of 20348 IU/L. The estimated ges-
tational age was seven weeks and six days by last 
menstrual period. Her past obstetrical history included 
three pregnancies with one full term delivery, one 
preterm delivery, and one therapeutic abortion. The 
patient was transferred from a community hospital to 
our tertiary center for further management.
Discussion
Chest pain in pregnant women is rarely due to myocar-
dial infarction. Pulmonary, gastrointestinal, psychiat-
ric, neuromuskuloskeletal, along with non-ischemic 
cardiac causes of chest pain must be considered in 
these patients. The incidence of myocardial infarc-
tion in pregnancy has been estimated to be 6.2 per 
100 000 deliveries with a mortality rate of 5.1%–11% 
in recent reviews.1,2 Prior estimates of mortality have 
reported it as substantially higher at 37% and esti-
mates  of  incidence  substantially  lower  at  2.8  per 
100 000 deliveries.1,3 This incidence is approximately 
3–4 times higher than the estimated age associated risk 
for non-pregnant women.2 The decreased mortality 
and  increased  incidence  in  the  recent  literature  is 
likely due to use of more sensitive and specific serum 
cardiac markers, such as troponins, identifying more 
cases of subendocardial myocardial injury as well as 
the increasing cardiovascular risks, such as advancing 
maternal age.1 In a nationwide US population based 
study of acute myocardial infarction (AMI) during 
pregnancy performed between 2000 and 2002, the 
anterior coronary circulation was found to be more 
commonly involved with 20% of reported infarctions 
occurring in this territory.1 Although not elaborated 
on within the original articles, the preponderance of 
anterior circulation culprit vessels in AMI may be due 
to the greater clinical presentation of these patients, 
while missing the smaller myocardial infarctions in 
the other vascular territories. The timing of MI in 
pregnancy varies. Ladner et al found that in pregnant 
women with AMI, 38% occurred in the antepartum, 
21% occurred in the intrapartum, and 41% occurred 
in the 6-week postpartum period.4 Within pregnancy, 
Badui and colleagues identified that women in the third 
trimester had the highest risk of AMI.5 The increased 
stroke volume and heart rate during pregnancy causes 
an increased myocardial oxygen demand, while the 
decreased diastolic blood pressure and related physio-
logic anemia result in decreased myocardial perfusion 
that may contribute to the ischemia when coronary 
blood flow is compromised. With labour, myocardial 
ischemia may be precipitated by a further increase in ACs in pregnancy
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Figure 1. Twelve-lead electrocardiogram showing sT segment depression in leads V4 and V5.Wright et al
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myocardial oxygen demand driven by pain, uterine 
contraction, and anxiety. After delivery, caval com-
pression is relieved and blood flow is shifted from 
the uterus back to the systemic circulation resulting in 
further stress on the myocardium and likely contrib-
uting to the increased incidence of myocardial infarc-
tion in the puerperium. With a compromise in the 
coronary blood flow, the high demand physiological 
state of normal pregnancy would precipitate myocar-
dial ischemia and potentially infarction.2 James et al 
reviewed the coronary anatomy through angiography 
and autopsy of pregnant women diagnosed with AMI 
and found that 40% had evidence of atherosclero-
sis with or without thrombosis, 8% had thrombosis 
without  atherosclerosis,  27%  had  coronary  artery 
dissections and 13% had normal coronaries.1 In the 
general population, nearly all cases of acute myo-
cardial infarction are due to coronary atherosclerotic 
disease and acute plaque rupture resulting in coro-
nary artery occlusion. Rarely, vasculitic syndromes, 
hypercoagulable  states,  coronary  artery  spasm, 
increased myocardial demand, coronary emboli, con-
genital  coronary  anomalies,  trauma  and  aneurysm 
may  cause AMI.6  The  increased  events  associated 
with thrombosis without atherosclerosis, vasospasm 
and coronary artery dissection may be related to the 
physiological alterations associated with pregnancy. 
Pregnancy is a known hypercoagulable state.7 The 
association of thrombophilia with MI in pregnancy 
may be due to the increased testing for this in this 
particular population.1 In regards to vasospasm, the 
pregnant woman has more reactive vessels to norepi-
nephrine and angiotensin II, has associated endothe-
lial dysfunction and has an increased renin secretion 
and  angiotensin  activity  associated  with  uterine 
malperfusion with the supine position and the use of 
ergot derivatives to control post-partum hemorrhage 
all may contribute.8 This vasospasm may also be the 
precipitating mechanism for thrombosis in coronary 
vessels that have no evidence of atherosclerosis, with 
the spasm impeding blood flow and the physiologic 
hypercoagulable state resulting in a thrombosis.8
The risk factors for AMI are also commonly seen 
in pregnancy, including diabetes mellitus, smoking, 
advanced maternal age, dyslipidemia, significant fam-
ily history and hypertension.1,2 In addition novel risk 
factors such as black race, pre-eclamplsia, eclampsia, 
anemia, migraine headaches and thrombophilia have 
been identified.1,4 The associated risk with migraines 
may be due to overall “vasospastic” disorder of the 
woman or due to heightened awareness of the physi-
cian for possible ACS events in these patients.1 The 
association of pre-eclampsia and eclamplsia may be 
due to endothelial dysfunction that has been shown 
to persist up to one year post partum.9 The increased 
incidence of coronary dissection is thought to be due 
to the changes in progesterone resulting in several 
structural and biochemical changes within the ves-
sel wall; however, other theories include changes in 
eosinophil activity and decreased prostacyclin activ-
ity have been postulated. It is these systemic changes 
in  conjunction  with  the  physiological  changes  of 
increased blood volume and cardiac output that likely 
result in increased shear forces that result in dissection 
occurring not only in single vessels, but frequently in 
multiple coronary arteries.2
The treatment of ACS has been well established 
for  the  non-pregnant  patient,  but  many  uncertain-
ties remain in the management of pregnant patient 
which may delay treatment. A classification scheme 
has been established to identify the associated risks 
with  certain  medications  in  pregnancy  (Table  1).6 
Nitroglycerine (Class B) is widely used for ischemic 
pain,  however  there  are  concerns  about  maternal 
hypotension  and  uterine  malperfusion.1,2  Studies 
are required to fully elucidate the effect of nitrates 
in  pregnancy.10  Heparin  (unfractionated  heparin 
Class  C,  low-molecular  weight  heparin  LMWH 
Class B) has been proven to be safe in pregnancy 
in numerous studies, however it is recommended to 
stop heparin prior to delivery and monitoring anti-
Xa levels if LMWH is used due to the pregnancy 
associated pharmacokinetic changes.11 Beta-blockers 
(Metoprolol Class B, Atenolol Class C) have been 
used successfully; however there are anecdotal reports 
of fetal bradycardia, hypoglycemia, hyperbilirubine-
mia, and apnea.2 A Cochrane review looking at oral 
beta blockers for use in treatment of mild to moderate 
hypertension in pregnant women found that there was 
a trend toward small for gestational age infants, but 
the results were skewed by a small outlier trial. There 
was insufficient data to comment on perinatal mortal-
ity or preterm delivery.12 Atenolol has been linked to a 
possible increase in fetal growth restriction, especially 
when used in the first trimester.13 ASA (Class C) is 
debateable for use during pregnancy because animal ACs in pregnancy
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studies have shown increased incidence of fissure of 
spine and skull, facial and eye defects, and malforma-
tions of the central nervous system (CNS), viscera, 
and skeleton.2,10 Chronic use of high dose ASA during 
pregnancy should be avoided because of increased 
fetal hemorrhage, increased perinatal mortality, intra-
uterine growth restriction and teratogenic effects.2,6 
A meta-analysis looking at antiplatelet agents found 
that low dose ASA is safe in pregnancy.14 Clopidogrel 
(Class B) has very limited data for its use in pregnancy. 
It is recommended that Clopidogrel be stopped 1 week 
prior to any regional anesthesia procedures.2 Glyco-
protein IIb/IIIa inhibitors (Eptifibatide and Tirofiban 
Class B, Abciximab Class C) have not been studied 
in pregnant patients as all randomized trials of these 
agents excluded pregnant patients. These drugs can-
not be recommended in pregnant patients, however if 
they are used a C-section delivery is recommended 
to decrease the potential for fetal intracranial hemor-
rhage.2 Angiotensin converting enzyme (ACE) inhib-
itors and angiotensin receptor blockers (ARBs) are 
contraindicated in pregnancy due to teratogenic side 
effects. Many animal and human studies have found 
that ACE inhibitors and ARBs cause multiple birth 
defects including renal dysgenesis, oligohydramnios, 
IUGR, prematurity, bone malformations, limb con-
tractures, death and multiple others.6,15 A recent retro-
spective analysis of fetuses exposed to ACE inhibitors 
in the first trimester identified ACE inhibitors as an 
independent risk factor for developing malformations 
of the cardiovascular and CNS.16 Statins (Class X) 
are not recommended in pregnancy as information 
on use in pregnancy is limited. Although laboratory 
models show potential placental growth disruption 
and animal studies have shown skeletal abnormali-
ties and increases in mortality, a recent systematic 
review found that most data of human teratogenic-
ity were only case reports and that the overall risk is 
likely minimal. The authors stated that statin expo-
sure did not warrant termination of pregnancy as a 
sole reason.2,17,18 A prospective cohort of 134 women 
inadvertently exposed to lovastatin and simvastatin 
found no difference in the incidence of adverse preg-
nancy outcomes.19
The  use  of  invasive  catheter  procedures  for 
management of AMI in pregnancy is also not clearly 
identified.  Numerous  case  studies  have  been  pub-
lished that describe results of both invasive and con-
servative management. In one report a patient was 
managed conservatively with ASA and beta-blockers, 
while waiting for the post-partum period to undergo 
cardiac catheterization. Other reports have described 
treating  pregnant  women  with  early  percutaneous 
coronary intervention (PCI) and stent placement. Both 
reported favorable fetal and maternal outcomes.20–22 
Bare metal stents have been used with success in the 
literature; however, there is limited data for the use 
of  drug  eluting  stents  and  its  necessary  long-term 
clopidogrel treatment.2
The  teratogenic  effects  of  radiation  were  first 
reported in 1929 when Goldstein and Murphy observed 
a  high  rate  of  micorcephaly  and  reduced  cranial 
circumference in women who had undergone radia-
tion treatment for uterine cancer during pregnancy. 
Table 1. Classification for safety of medication use during pregnancy.6
category Interpretation
A Controlled studies show no risk  
Adequate, well-controlled studies in pregnant women have failed to demonstrate risk to the fetus.
B No evidence of risk in humans  
Either animal findings show risk (but human findings do not) or, if no adequate human studies have 
been done, animal findings are negative.
C Risk cannot be ruled out  
Human studies are lacking and animal studies are either positive for fetal risk or lacking as well. 
However, potential benefits may justify the potential risk.
D Positive evidence of risk  
Investigational or post-marketing data show risk to fetus. Nevertheless, potential benefits may 
outweigh the risk.
X Contraindicated in pregnancy  
studies in animals or humans, or investigational or post-marketing reports have shown fetal risk 
which clearly outweighs any possible benefit to the patient.Wright et al
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While many studies have shown that a fetal dose of 
5 rads is not related to teratogenicity at any period 
of gestation, the most vulnerable time for the fetus 
is 8–15 weeks of gestation.23 Coronary angiography 
exposes  patients  to  2.5–5.0  mSv  (equivalent  to 
125–250  chest  x-rays),  and  percutaneous  coronary 
intervention exposes patients to 5.0–15.0 mSv (equiv-
alent  to  115–1000  chest  x-rays),24  which  are  both 
below the threshold for teratogenicity at any gesta-
tional age. The amount of radiation that reaches the 
fetus is a percentage of the total amount delivered to 
the patient and depends on the body parts being irra-
diated and the type of protection used. No necessary 
radiodiagnostic examination that is clinically justifi-
able should be avoided due to pregnancy, and pro-
tective measures for the mother and fetus should be 
taken. Other diagnostic procedures that are equally as 
effective but not as dangerous to the fetus should be 
preferentially used.
A number of therapies ranging from multiple drugs 
to PCI are available for the pregnant patient present-
ing with ACS. It is important to weigh the risks and 
benefits of each potential therapy and tailor the man-
agement according to the clinical presentation.
Return to the case
The patient was started on ASA, beta-blockers, and 
intravenous  unfractionated  heparin.  Nitroglycerine 
spray was prescribed to be used as needed for chest 
pain relief. The obstetrics team was consulted to guide 
in  management.  A  quantitative  β-hCG  and  pelvic 
ultrasound were arranged to verify the viability of the 
pregnancy prior to starting medications with known 
teratogenic  side  effects  and  unclear  risk  profiles. 
PCI was discussed however not pursued as she had a 
normal left ventricular ejection fraction, no recurrent 
chest pain, no electrical or mechanical complications. 
A pelvic ultrasound showed an intrauterine pregnancy 
with no fetal heartbeat, consistent with fetal demise. 
Expectant management of the fetus was chosen and 
follow-up ultrasound was arranged with the obstet-
rics team. The cardiology team arranged follow-up 
regarding  long  term  medications  and  planning  for 
further risk stratification.
Although ACS in pregnancy has been historically 
uncommon,  the  increasing  prevalence  of  athero-
sclerotic risk factors in women of child bearing age 
combined with the normal physiological changes of 
pregnancy will cause the incidence of this presenta-
tion to increase in clinical practice. It is important that 
physicians are familiar with the clinical presentation, 
risk factors, potential management options and their 
interactions with both the pregnant female and the 
fetus.
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